About our agreements
Our agreements help people living in low- and middle-income countries access vaccines, medicines, diagnostics and other technologies more quickly.
Health areas we work in
We speed up access to vaccines, medicines, diagnostics and technologies designed to reduce disease and death.
Initially, our agreements focused on improving access to medical innovations to tackle infectious diseases. Low- and middle-income countries continue to face a disproportionate health burden from infectious diseases, despite decades of progress.
We recently expanded our work to tackle non-communicable diseases too, such as cancer and sickle cell disease. We believe we can make a significant impact on the growing burden of non-communicable diseases in low- and middle-income countries, helping millions more people to live longer, healthier lives.
Health products we support
Our agreements help to increase access to a wide range of medical innovations. To date, we have supported access to vaccines, therapeutics, and diagnostics, as well as essential supplies, such as syringes and clinical equipment, to tackle COVID-19.
We support products that are ready for market. They must have successfully completed clinical trials and been approved by a stringent regulatory authority or prequalified by the World Health Organization (WHO).
We are not involved in research and development of new products. We recognise that other partners are better placed to support the development of new innovations. MedAccess focuses on helping ensure these new innovations reach the people who need them as quickly as possible.
Where we work
To date, we have reached people in over 120 countries.
Our agreements focus on increasing access to medical innovations for people in low- and middle-income countries that are:
- Eligible for official development assistance as defined by the Organisation for Economic Co-operation and Development (OECD)
- At least 50% of patients receiving products as the result of an agreement must be based in British International Investment (BII) priority territories (sub-Saharan Africa and South Asia).
